These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24444350)

  • 21. Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge.
    Malherbe DC; Vang L; Mendy J; Barnette PT; Spencer DA; Reed J; Kareko BW; Sather DN; Pandey S; Wibmer CK; Robins H; Fuller DH; Park B; Lakhashe SK; Wilson JM; Axthelm MK; Ruprecht RM; Moore PL; Sacha JB; Hessell AJ; Alexander J; Haigwood NL
    Front Immunol; 2020; 11():626464. PubMed ID: 33658998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.
    Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection.
    Marasini B; Vyas HK; Lakhashe SK; Hariraju D; Akhtar A; Ratcliffe SJ; Ruprecht RM
    AIDS; 2021 Dec; 35(15):2423-2432. PubMed ID: 34402452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens.
    Seaman MS; Leblanc DF; Grandpre LE; Bartman MT; Montefiori DC; Letvin NL; Mascola JR
    Virology; 2007 Oct; 367(1):175-86. PubMed ID: 17599382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.
    Watkins JD; Sholukh AM; Mukhtar MM; Siddappa NB; Lakhashe SK; Kim M; Reinherz EL; Gupta S; Forthal DN; Sattentau QJ; Villinger F; Corti D; Ruprecht RM;
    AIDS; 2013 Jun; 27(9):F13-20. PubMed ID: 23775002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges.
    Gong S; Lakhashe SK; Hariraju D; Scinto H; Lanzavecchia A; Cameroni E; Corti D; Ratcliffe SJ; Rogers KA; Xiao P; Fontenot J; Villinger F; Ruprecht RM
    Front Immunol; 2021; 12():705592. PubMed ID: 34413855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.
    Saunders KO; Santra S; Parks R; Yates NL; Sutherland LL; Scearce RM; Balachandran H; Bradley T; Goodman D; Eaton A; Stanfield-Oakley SA; Tartaglia J; Phogat S; Pantaleo G; Esteban M; Gomez CE; Perdiguero B; Jacobs B; Kibler K; Korber B; Montefiori DC; Ferrari G; Vandergrift N; Liao HX; Tomaras GD; Haynes BF
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.
    Rudicell RS; Kwon YD; Ko SY; Pegu A; Louder MK; Georgiev IS; Wu X; Zhu J; Boyington JC; Chen X; Shi W; Yang ZY; Doria-Rose NA; McKee K; O'Dell S; Schmidt SD; Chuang GY; Druz A; Soto C; Yang Y; Zhang B; Zhou T; Todd JP; Lloyd KE; Eudailey J; Roberts KE; Donald BR; Bailer RT; Ledgerwood J; ; Mullikin JC; Shapiro L; Koup RA; Graham BS; Nason MC; Connors M; Haynes BF; Rao SS; Roederer M; Kwong PD; Mascola JR; Nabel GJ
    J Virol; 2014 Nov; 88(21):12669-82. PubMed ID: 25142607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Zhang P; Narayanan E; Liu Q; Tsybovsky Y; Boswell K; Ding S; Hu Z; Follmann D; Lin Y; Miao H; Schmeisser H; Rogers D; Falcone S; Elbashir SM; Presnyak V; Bahl K; Prabhakaran M; Chen X; Sarfo EK; Ambrozak DR; Gautam R; Martin MA; Swerczek J; Herbert R; Weiss D; Misamore J; Ciaramella G; Himansu S; Stewart-Jones G; McDermott A; Koup RA; Mascola JR; Finzi A; Carfi A; Fauci AS; Lusso P
    Nat Med; 2021 Dec; 27(12):2234-2245. PubMed ID: 34887575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.
    Pauthner MG; Nkolola JP; Havenar-Daughton C; Murrell B; Reiss SM; Bastidas R; Prévost J; Nedellec R; von Bredow B; Abbink P; Cottrell CA; Kulp DW; Tokatlian T; Nogal B; Bianchi M; Li H; Lee JH; Butera ST; Evans DT; Hangartner L; Finzi A; Wilson IA; Wyatt RT; Irvine DJ; Schief WR; Ward AB; Sanders RW; Crotty S; Shaw GM; Barouch DH; Burton DR
    Immunity; 2019 Jan; 50(1):241-252.e6. PubMed ID: 30552025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
    Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
    J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.
    Shingai M; Donau OK; Schmidt SD; Gautam R; Plishka RJ; Buckler-White A; Sadjadpour R; Lee WR; LaBranche CC; Montefiori DC; Mascola JR; Nishimura Y; Martin MA
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19769-74. PubMed ID: 23129652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.
    Hora B; Li H; Shen X; Martin M; Chen Y; Berry M; Evangelous T; Macintyre AN; Arus-Altuz A; Wang S; Singh A; Zhao C; De Naeyer N; DeMarco T; Kuykendall C; Gurley T; Saunders KO; Denny T; Moody MA; Misamore J; Lewis MG; Wiehe K; Cain DW; Montefiori DC; Shaw GM; Williams WB
    Cell Rep; 2023 Mar; 42(3):112255. PubMed ID: 36924501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
    Cox JH; Ferrari MG; Earl P; Lane JR; Jagodzinski LL; Polonis VR; Kuta EG; Boyer JD; Ratto-Kim S; Eller LA; Pham DT; Hart L; Montefiori D; Ferrari G; Parrish S; Weiner DB; Moss B; Kim JH; Birx D; VanCott TC
    Vaccine; 2012 Feb; 30(10):1830-40. PubMed ID: 22234262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques.
    Styles TM; Gangadhara S; Reddy PBJ; Sahoo A; Shiferaw A; Welbourn S; Kozlowski PA; Derdeyn CA; Velu V; Amara RR
    Front Immunol; 2022; 13():914969. PubMed ID: 35935987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.